Biomedical

Search documents
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-14 14:10
Core Insights - ADC Therapeutics SA reported a quarterly loss of $0.36 per share, which is better than the Zacks Consensus Estimate of a loss of $0.38, and an improvement from a loss of $0.56 per share a year ago [1] - The company achieved revenues of $23.03 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 26.94% and up from $18.05 million year-over-year [2] - The stock has underperformed, losing approximately 33.7% since the beginning of the year, while the S&P 500 has gained 0.1% [3] Financial Performance - Over the last four quarters, ADC Therapeutics has surpassed consensus EPS estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.39 on revenues of $18.73 million, and for the current fiscal year, it is -$1.65 on revenues of $75.43 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which ADC Therapeutics belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, particularly following management's commentary on the earnings call [3][4] - The current Zacks Rank for ADC Therapeutics is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-14 13:45
Company Performance - Arbutus Biopharma reported a quarterly loss of $0.13 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, and compared to a loss of $0.10 per share a year ago, indicating an earnings surprise of -44.44% [1] - The company posted revenues of $1.76 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 10.25%, and showing an increase from year-ago revenues of $1.53 million [2] - Over the last four quarters, Arbutus has surpassed consensus EPS estimates just once, but has topped consensus revenue estimates three times [2] Stock Outlook - The immediate price movement of Arbutus shares will depend on management's commentary during the earnings call, as the stock has lost about 2.5% since the beginning of the year, while the S&P 500 has gained 0.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.02 on $1.6 million in revenues, and -$0.20 on $7.35 million in revenues for the current fiscal year [7] - The estimate revisions trend for Arbutus is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Arbutus belongs, is currently in the top 30% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]
Kamada (KMDA) Q1 Earnings Match Estimates
ZACKS· 2025-05-14 13:10
分组1 - Kamada reported quarterly earnings of $0.07 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.04 per share a year ago [1] - The company posted revenues of $44.02 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 5.28%, compared to $37.74 million in the same quarter last year [2] - Kamada shares have increased approximately 13.1% since the beginning of the year, outperforming the S&P 500's gain of 0.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $44.55 million, and for the current fiscal year, it is $0.27 on revenues of $179.87 million [7] - The Medical - Biomedical and Genetics industry, to which Kamada belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8]
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-13 22:40
Financial Performance - Inovio Pharmaceuticals reported a quarterly loss of $0.51 per share, better than the Zacks Consensus Estimate of a loss of $0.74, and an improvement from a loss of $1.31 per share a year ago, representing an earnings surprise of 31.08% [1] - The company posted revenues of $0.07 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 30%, compared to zero revenues a year ago [2] Stock Performance - Inovio shares have increased by approximately 6% since the beginning of the year, while the S&P 500 has declined by 0.6% [3] - The current Zacks Rank for Inovio is 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.60 on revenues of $0.05 million, and for the current fiscal year, it is -$2.27 on revenues of $7.7 million [7] - The Medical - Biomedical and Genetics industry, to which Inovio belongs, is currently in the top 35% of Zacks industries, suggesting a favorable outlook for stocks within this sector [8]
Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates
ZACKS· 2025-05-13 22:20
Company Performance - Eton Pharmaceuticals reported quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share, compared to a loss of $0.03 per share a year ago, representing an earnings surprise of -22.22% [1] - The company posted revenues of $17.28 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 6.71%, and this is an increase from year-ago revenues of $7.97 million [2] - Over the last four quarters, Eton Pharmaceuticals has surpassed consensus revenue estimates three times [2] Stock Performance - Eton Pharmaceuticals shares have increased approximately 30.3% since the beginning of the year, while the S&P 500 has declined by -0.6% [3] - The current consensus EPS estimate for the coming quarter is $0.07 on revenues of $16.7 million, and for the current fiscal year, it is $0.53 on revenues of $75.35 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Eton Pharmaceuticals belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]
Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-13 22:20
Group 1 - Seer, Inc. reported a quarterly loss of $0.34 per share, which was better than the Zacks Consensus Estimate of a loss of $0.37, representing an earnings surprise of 8.11% [1] - The company posted revenues of $4.21 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 26.28%, and showing an increase from $3.07 million in the same quarter last year [2] - Seer has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] Group 2 - The stock has underperformed the market, losing about 18.2% since the beginning of the year, compared to a decline of 0.6% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.37 on revenues of $3.75 million, and for the current fiscal year, it is -$1.45 on revenues of $17.48 million [7] - The Medical - Biomedical and Genetics industry, to which Seer belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8]
Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates
ZACKS· 2025-05-13 22:20
Exelixis (EXEL) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 47.62%. A quarter ago, it was expected that this drug developer would post earnings of $0.51 per share when it actually produced earnings of $0.55, delivering a surprise of 7.84%.Over the last four quarters, the company h ...
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates
ZACKS· 2025-05-13 22:10
Group 1 - Lexicon Pharmaceuticals reported a quarterly loss of $0.07 per share, better than the Zacks Consensus Estimate of a loss of $0.10, and an improvement from a loss of $0.20 per share a year ago, resulting in an earnings surprise of 30% [1] - The company posted revenues of $1.26 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 23.52%, compared to year-ago revenues of $1.13 million [2] - Lexicon shares have declined approximately 8.8% since the beginning of the year, while the S&P 500 has seen a decline of -0.6% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $2.37 million, and for the current fiscal year, it is -$0.37 on revenues of $15.43 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 35% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - Lexicon has a Zacks Rank of 2 (Buy), suggesting that the stock is expected to outperform the market in the near future [6]
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates
ZACKS· 2025-05-13 22:10
Company Performance - Spero Therapeutics reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.55, representing an earnings surprise of 54.55% [1] - The company posted revenues of $5.87 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 46.60%, compared to revenues of $9.27 million a year ago [2] - Over the last four quarters, Spero Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Outlook - Spero Therapeutics shares have declined approximately 40.8% since the beginning of the year, while the S&P 500 has only declined by 0.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.32 on $11 million in revenues, and for the current fiscal year, it is -$2.32 on $60 million in revenues [7] - The estimate revisions trend for Spero Therapeutics is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Spero Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Spero Therapeutics' stock performance [5]
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
ZACKS· 2025-05-13 22:10
Financial Performance - Lineage Cell reported a quarterly loss of $0.02 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.04 per share a year ago [1] - The company posted revenues of $1.5 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 31.73%, but showing a slight increase from $1.44 million year-over-year [2] - Over the last four quarters, Lineage Cell has surpassed consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2][1] Stock Performance - Lineage Cell shares have declined approximately 4.7% since the beginning of the year, compared to a decline of 0.6% for the S&P 500 [3] - The current Zacks Rank for Lineage Cell is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $2.25 million, and for the current fiscal year, it is -$0.07 on revenues of $16.05 million [7] - The trend of estimate revisions for Lineage Cell is mixed, which could change following the recent earnings report [6] Industry Context - Lineage Cell operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 35% of over 250 Zacks industries [8] - Research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]